Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ALGS

Aligos Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1799448Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$2.0M
Net Income FY2025
$(24.0M)
EPS (Basic, as reported)
$-2.45
Net Margin FY2025
-1106.7%
ROE FY2025
-45.2%
Total Equity
$54.0M
Shares Out
43M
Business description

Aligos Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 0 → 2
Fiscal yearFY2019FY2020FY2021FY2022⚑FY2023⚑FY2024⚑FY2025
Revenue—000642
Research & development(44)(80)(104)(85)(73)(70)(69)
General & administrative(10)(18)(29)(26)(31)(23)(21)
Total operating expenses(54)(98)(133)(111)(104)(93)(90)
Operating income(54)(98)(128)(98)(88)(89)(88)
Pre-tax income(52)(108)(128)(96)(87)(131)(24)
Income tax expense0000(1)00
Net income(52)(109)(128)(96)(88)(131)(24)
EPS — basic———($2.25)($1.36)($20.94)($2.45)
EPS — diluted———($2.25)($1.36)($20.94)($2.45)
Shares outstanding — basic (M)———4364610
Shares outstanding — diluted (M)———4364610
  • ⚑ Weighted-average shares changed ×1.49 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ÷11.11 between FY2023 and FY2024 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×1.67 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.